Stock KURA KURA ONCOLOGY, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Kura Oncology, Inc.

Equities

KURA

US50127T1097

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-19 pm EDT 		5-day change 1st Jan Change
17.53 USD -0.85% Intraday chart for Kura Oncology, Inc. -10.01% +21.91%
Mar. 14 Transcript : Kura Oncology, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-14-2024 09:00 AM
Mar. 06 Kura Oncology Reports First Patient Dosed in Trial of KO-2806 Plus Cabozantinib in Renal Cell Carcinoma CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Kura Oncology to Participate in Stifel Targeted Oncology Forum
AQ
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AQ
Transcript : Kura Oncology, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-14-2024 09:00 AM
Kura Oncology Reports First Patient Dosed in Trial of KO-2806 Plus Cabozantinib in Renal Cell Carcinoma
AQ
Kura Oncology Reports First Patient Dosed in Trial of KO-2806 Plus Cabozantinib in Renal Cell Carcinoma
CI
KURA ONCOLOGY REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(4)
AQ
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AQ
Transcript : Kura Oncology, Inc., 2023 Earnings Call, Feb 27, 2024
Kura Oncology: Q4 Earnings Snapshot
AQ
Kura Oncology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Kura Oncology, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
CI
Kura Oncology Reports Fourth Quarter and Full Year 2023 Financial Results
AQ
Kura Oncology Doses First Patient in KOMET-008 Trial of Ziftomenib in Combination with Standards of Care, Including FLT3 Inhibitor, in Acute Myeloid Leukemia
AQ
Kura Oncology, Inc. Doses First Patient in KOMET-008 Trial of Ziftomenib in Combination with Standards of Care, Including FLT3 Inhibitor, in Acute Myeloid Leukemia
CI
Kura Oncology to Participate in Three Upcoming Investor Conferences
AQ
Kura Oncology to Report Fourth Quarter and Full Year 2023 Financial Results
AQ
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AQ
Kura Oncology Says Study of Leukemia Combination Therapy Yields Positive Early Data
MT
Transcript : Kura Oncology, Inc. - Special Call
Top Premarket Gainers
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. KURA Stock
  4. News Kura Oncology, Inc.